3月20日 - ** 制药商礼来公司（Eli Lilly <LLY.N>）股价上涨1.77%，至852.32美元
** 礼来公司（Eli Lilly）在印度推出 (link) 其重磅糖尿病和减肥药Mounjaro，击败了竞争对手诺和诺德（Novo Nordisk）NOVOb.CO。
** 这款每周注射一次的药物获得了印度药品监管机构的批准，价格为5毫克小瓶装4375卢比(（50.67美元）)，2.5毫克小瓶装3500卢比(（40.54美元）)，这是最低剂量
** 诺和诺德印度团队一直在推动全球领导层，最早在2025年就在印度推出减肥药Wegovy，而不是公司设定的2026年目标
** LLY股票年初至今上涨10%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.